HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Hemogenyx Pharmaceuticals has received IRB approval to begin a Phase I clinical trial of its lead therapy, HEMO-CAR-T, aimed at treating relapsed/refractory acute myeloid leukemia. This marks a significant step for the company in advancing a potentially groundbreaking treatment for a type of cancer with limited options. Investors may find this development promising as it could impact treatment and survival rates for AML.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
